Clinical Research Directory

Inclusion Criteria: * histologically-confirmed squamous cell carcinoma * primary lesions located in the thoracic esophagus * clinical stage cT4 or at least one group of lymph nodes invade the surrounding organs and unresectable lymph nodes * having not received neoadjuvant therapy * 18-75 years * ECOG performance status of 0 or 1 * no prior chemotherapy, radiotherapy, or immunotherapy for any cancers * adequate organ function * expectation of R0 resection * provision of written informed consent. Exclusion Criteria: * corticosteroid treatment (equivalent to prednisone \>10 mg/day) within 14 days before the first day of the drug administration * acquired immunodeficiency syndrome or active hepatitis B (DNA ≥ 104 copies/ml) or C (RNA ≥ 103 copies/ml) viral infections * history of pneumonitis or interstitial lung disease with clinical evidence, such as interstitial pneumonia and pulmonary fibrosis features on baseline CT scans * known or concurrent bleeding disorders or other uncontrolled diseases contraindicating surgical treatment * physical examination or clinical trial findings that can interfere with the results or put the patient at increased risk for treatment complications * comorbidities, including chronic pulmonary disease, poorly controlled hypertension, unstable angina, myocardial infarction within 6 months, and unstable mental disorders requiring therapy * allergy to drugs used in the study * participation in other clinical trials within 30 days before enrollment * ineligibility for participation based on the decision of investigators.